3 Mar 2006 22:12
What's New Friday March 3, 2006
What's New <whatsnew <at> BOBPARK.ORG>
2006-03-03 21:12:15 GMT
2006-03-03 21:12:15 GMT
WHAT'S NEW Robert L. Park Friday, 3 Mar 06 Washington, DC 1. GLUCOSAMINE AND CHONDROITIN: INEFFECTIVE FOR ARTHRITIS PAIN? We got a lot of mail last week about our comment on these popular dietary supplements. Based on an NIH-funded trial, reported in the New England Journal of Medicine, WN characterized G-C as "ineffective" for osteoarthritis knee pain. The study reported that: "Overall, glucosamine and chondroitin sulfate were not significantly better than a placebo in reducing knee pain by 20 percent." The double-blind trial was placebo controlled, and celecoxib (Celebrex) was used as a positive control. The problem is that the 1583 patients in the trial were divided into subsets based on severity of pain. Although it was ineffective overall, indignant WN readers pointed out that for the moderate-to-severe subset G-C "provided statistically significant pain relief compared to a placebo." Statisticians groaned: by dividing the cohort into subgroups, the outcome for a specific subset can usually be altered by fiddling with the boundaries. The bottom line in the NEJM study, incidentally, is the ubiquitous report ending, "continued research is needed to establish efficacy." 2. WE FEEL YOUR PAIN: WHAT'S NEW DOES A STUDY OF THE BOTTOM LINE. Much of the e-mail about G-C was anecdotal. Not just from people who used it themselves, but also those who had treated dogs, cats and horses with it(vets love G-C, and point out that pets don't respond to placebos). "The plural of anecdote," someone said, "is data." Although anecdotes are not blind; we decided to see what the data might tell us about What's New. First we divided the messages into subgroups. The groups ranged from,"He's just guessing," to "Park is a liar and must be getting paid under the(Continue reading)
RSS Feed